请输入关键字
请输入关键字
订购
*国家
中国
美国
中国香港
中国澳门
中国台湾
阿尔巴尼亚
阿尔及利亚
阿根廷
阿拉伯联合酋长国
阿鲁巴
阿曼
阿塞拜疆
阿森松岛
埃及
埃塞俄比亚
爱尔兰
爱沙尼亚
安道尔
安哥拉
安圭拉
安提瓜和巴布达
奥地利
奥兰群岛
澳大利亚
巴巴多斯
巴布亚新几内亚
巴哈马
巴基斯坦
巴拉圭
巴勒斯坦领土
巴林
巴拿马
巴西
白俄罗斯
百慕大
保加利亚
北马里亚纳群岛
贝宁
比利时
冰岛
波多黎各
波兰
波斯尼亚和黑塞哥维那
玻利维亚
伯利兹
博茨瓦纳
不丹
布基纳法索
布隆迪
朝鲜
赤道几内亚
丹麦
德国
迪戈加西亚岛
东帝汶
多哥
多米尼加共和国
多米尼克
俄罗斯
厄瓜多尔
厄立特里亚
法国
法罗群岛
法属波利尼西亚
法属圭亚那
法属南部领地
梵蒂冈
菲律宾
斐济
芬兰
佛得角
福克兰群岛
冈比亚
刚果(布)
刚果(金)
哥伦比亚
哥斯达黎加
格恩西岛
格林纳达
格陵兰
格鲁吉亚
古巴
瓜德罗普
关岛
圭亚那
哈萨克斯坦
海地
韩国
荷兰
荷属加勒比区
荷属圣马丁
黑山
洪都拉斯
基里巴斯
吉布提
吉尔吉斯斯坦
几内亚
几内亚比绍
加拿大
加纳
加纳利群岛
加蓬
柬埔寨
捷克
津巴布韦
喀麦隆
卡塔尔
开曼群岛
科科斯(基林)群岛
科摩罗
科索沃
科特迪瓦
科威特
克罗地亚
肯尼亚
库克群岛
库拉索
拉脱维亚
莱索托
老挝
黎巴嫩
立陶宛
利比里亚
利比亚
联合国
列支敦士登
留尼汪
卢森堡
卢旺达
罗马尼亚
马达加斯加
马恩岛
马尔代夫
马耳他
马拉维
马来西亚
马里
马其顿
马绍尔群岛
马提尼克
马约特
毛里求斯
毛里塔尼亚
美国本土外小岛屿
美属萨摩亚
美属维尔京群岛
蒙古
蒙特塞拉特
孟加拉国
秘鲁
密克罗尼西亚
缅甸
摩尔多瓦
摩洛哥
摩纳哥
莫桑比克
墨西哥
纳米比亚
南非
南极洲
南乔治亚和南桑威奇群岛
南苏丹
瑙鲁
尼加拉瓜
尼泊尔
尼日尔
尼日利亚
纽埃
挪威
诺福克岛
帕劳
皮特凯恩群岛
葡萄牙
日本
瑞典
瑞士
萨尔瓦多
萨摩亚
塞尔维亚
塞拉利昂
塞内加尔
塞浦路斯
塞舌尔
沙特阿拉伯
圣巴泰勒米
圣诞岛
圣多美和普林西比
圣赫勒拿
圣基茨和尼维斯
圣卢西亚
圣马丁岛
圣马力诺
圣皮埃尔和密克隆群岛
圣文森特和格林纳丁斯
斯里兰卡
斯洛伐克
斯洛文尼亚
斯瓦尔巴和扬马延
斯威士兰
苏丹
苏里南
所罗门群岛
索马里
塔吉克斯坦
泰国
坦桑尼亚
汤加
特克斯和凯科斯群岛
特里斯坦-达库尼亚群岛
特立尼达和多巴哥
突尼斯
图瓦卢
土耳其
土库曼斯坦
托克劳
瓦利斯和富图纳
瓦努阿图
危地马拉
委内瑞拉
文莱
乌干达
乌克兰
乌拉圭
乌兹别克斯坦
希腊
西班牙
西撒哈拉
新加坡
新喀里多尼亚
新西兰
匈牙利
休达及梅利利亚
叙利亚
牙买加
亚美尼亚
也门
伊拉克
伊朗
以色列
意大利
印度
印度尼西亚
英国
英属维尔京群岛
英属印度洋领地
约旦
越南
赞比亚
泽西岛
乍得
直布罗陀
智利
中非共和国
*省份
*城市
*姓名
*电话
*单位
*职位
*邮箱
*请输入验证码
*验证码
B-hCD200/hCD200R mice
Strain Name
C57BL/6-Cd200tm1(CD200)Bcgen Cd200r1tm1(CD200R1)Bcgen/Bcgen 
Common Name  B-hCD200/hCD200R mice
Background C57BL/6 Catalog number 111888
Aliases 

CD200, MOX1, MOX2, MRC, OX-2, CD200 molecule;

CD200R1, CD200R, HCRTR2, MOX2R, OX2R, CD200 receptor 1

Description


  • CD200 is broadly distributed on cells from both hematopoietic and non-hematopoietic origin, and is conserved between humans and rodents. CD200R expression is limited to lymphoid and myeloid cell lineages. When  triggered  by  its  ligand  CD200, CD200R  can  recruit  Dok2  and  RasGAP  that  have  a  negative  effect  on Ras  activation. Compared with normal cells or their tissue counterparts, CD200 is overexpressed in various cancers such as kidney cancer, head and neck cancer, and colon cancer. The upregulation of CD200 on various human cancer cells has an immunosuppressive effect on immune cells within the tumor microenvironment, creating conditions that favor tumor development, growth, and spread. This indicates that CD200 is a potential therapeutic target and prognostic factor for a range of malignant tumors.

  • The genomes of the mouse Cd200 gene and Cd200r1 gene are replaced by the human CD200 genome and CD200R1 genome in B-hCD200/hCD200R mice, respectively.

  • Human CD200 and CD200R were detectable in homozygous B-hCD200/hCD200R mice.

  • The blood indicators of B-hCD200/hCD200R mice are normal.

  • Anti-hCD200 antibody combination with anti-mPD-1 antibody was efficacious in controlling tumor growth in B-hCD200/hCD200R mice.

  • This product is used for pharmacodynamics and safety evaluation of tumors and other autoimmune diseases such as atopic dermatitis and urticaria.


Targeting strategy



Gene targeting strategy for B-hCD200/hCD200R mice.

The exons 1-5 of mouse Cd200 gene that encode signal peptide, extracellular domain, transmembrane domain and cytoplasmic region are replaced by human counterparts in B-hCD200/hCD200R mice. The promoter, 5’UTR and 3’UTR region of the mouse gene are retained. The human CD200 expression is driven by endogenous mouse Cd200 promoter, while mouse Cd200 gene transcription and translation will be disrupted.

The exons 2-5 of mouse Cd200r1 gene that encode extracellular domain are replaced by human counterparts in B-hCD200/hCD200R mice. The genomic region of mouse Cd200r1 gene that encodes transmembrane domain and cytoplasmic portion is retained. The promoter, 5’UTR and 3’UTR region of the mouse gene are also retained. The chimeric CD200R1 expression is driven by endogenous mouse Cd200r1 promoter, while mouse Cd200r1 gene transcription and translation will be disrupted.


Protein expression analysis in spleen


from clipboard


Strain specific CD200 expression analysis in wild-type C57BL/6 mice and homozygous humanized B-hCD200/hCD200R mice by flow cytometry. Splenocytes were collected from wild-type C57BL/6 mice and homozygous B-hCD200/hCD200R mice. Protein expression was analyzed with anti-mouse CD200 antibody (eBioscience™, 12-5200-82) and anti-human CD200 antibody (eBioscience™, 17-9200-41) by flow cytometry. Mouse CD200 was only detectable in wild-type C57BL/6 mice. Human CD200 was exclusively detectable in homozygous B-hCD200/hCD200R mice, but not in wild-type C57BL/6 mice.


Protein expression analysis on peritoneal exudative macrophages


from clipboard


Strain specific CD200R expression analysis in wild-type C57BL/6 mice and homozygous humanized B-hCD200/hCD200R mice by flow cytometry. Peritoneal exudative macrophages were collected from wild-type C57BL/6 mice and homozygous B-hCD200/hCD200R mice. Protein expression was analyzed with anti-mouse CD200R antibody (Biolegend, 123915) and anti-human CD200R antibody (Biolegend, 329305) by flow cytometry. Mouse CD200R was only detectable in wild-type C57BL/6 mice. Human CD200R was exclusively detectable in homozygous B-hCD200/hCD200R mice, but not in wild-type C57BL/6 mice.


Frequency of leukocyte subpopulations in spleen


from clipboard


Frequency of leukocyte subpopulations in spleen by flow cytometry. Splenocytes were isolated from wild-type C57BL/6 mice and homozygous B-hCD200/hCD200R mice (female, 8-week-old, n=3). A. Flow cytometry analysis of the splenocytes was performed to assess the frequency of leukocyte subpopulations. B. Frequency of T cell subpopulations. Percentages of T cells, B cells, NK cells, DCs, monocytes, macrophages, neutrophils, CD4+ T cells, CD8+ T cells and Tregs in B-hCD200/hCD200R mice were similar to those in C57BL/6 mice, demonstrating that humanization of CD200 and CD200R do not change the frequency or distribution of these cell types in spleen. Values are expressed as mean ± SEM.


Frequency of leukocyte subpopulations in lymph node


from clipboard

Frequency of leukocyte subpopulations in lymph node by flow cytometry. Leukocytes were isolated from wild-type C57BL/6 mice and homozygous B-hCD200/hCD200R mice (female, 8-week-old, n=3). A. Flow cytometry analysis of the leukocytes was performed to assess the frequency of leukocyte subpopulations. B. Frequency of T cell subpopulations. Percentages of T cells, B cells, NK cells, CD4+ T cells, CD8+ T cells and Tregs in B-hCD200/hCD200R mice were similar to those in C57BL/6 mice, demonstrating that humanization of CD200 and CD200R do not change the frequency or distribution of these cell types in lymph node. Values are expressed as mean ± SEM.


Frequency of leukocyte subpopulations in blood


from clipboard


Frequency of leukocyte subpopulations in blood by flow cytometry. Blood cells were isolated from wild-type C57BL/6 mice and homozygous B-hCD200/hCD200R mice (female, 8-week-old, n=3). A. Flow cytometry analysis of the blood cells was performed to assess the frequency of leukocyte subpopulations. B. Frequency of T cell subpopulations. Percentages of T cells, B cells, NK cells, DCs, monocytes, macrophages, neutrophils, CD4+ T cells, CD8+ T cells and Tregs in B-hCD200/hCD200R mice were similar to those in C57BL/6 mice, demonstrating that humanization of CD200 and CD200R do not change the frequency or distribution of these cell types in blood. Values are expressed as mean ± SEM.


Hematology analysis


from clipboard


Complete blood count (CBC) of B-hCD200/hCD200R mice. Values are expressed as mean ± SD.


Biochemistry analysis


from clipboard

Biochemical test of B-hCD200/hCD200R mice. Values are expressed as mean ± SD.


Tumor growth curve & body weight changes


from clipboard


Subcutaneous tumor growth of B-hCD200 MC38 cells. B-hCD200 MC38 cells (5x105) and wild-type MC38 cells (5x105) were subcutaneously implanted into heterozygous B-hCD200/hCD200R mice (female, 7-week-old, n=6). Tumor volume and body weight were measured twice a week. (A) Average tumor volume. (B) Body weight. Volume was expressed in mm3 using the formula: V=0.5 X long diameter X short diameter2. Results indicate that B-hCD200 MC38 cells were able to establish tumors in vivo and can be used for efficacy studies. Values are expressed as mean ± SEM.

Note: B-hCD200 MC38 cells only successfully formed tumors in B-hCD200/hCD200R mice, but did not form tumors in wild-type mice (data not shared).


Protein expression analysis of tumor tissue


from clipboard


CD200 expression evaluated on B-hCD200 MC38 tumor cells by flow cytometry. B-hCD200 MC38 cells were subcutaneously transplanted into heterozygous B-hCD200/hCD200R mice (n=6). Upon conclusion of the experiment, tumor cells were harvested and analyzed with anti-mouse CD200 antibody (Biolegend, 123810) and anti-human CD200 antibody (Biolegend, 329206) by flow cytometry. As shown, human CD200 was highly expressed on the surface of tumor cells. Therefore, B-hCD200 MC38 cells can be used for in vivo efficacy studies evaluating novel CD200 therapeutics.

Note: B-hCD200 MC38 cells only successfully formed tumors in B-hCD200/hCD200R mice, but did not form tumors in wild-type mice (data not shared).


In vivo efficacy of anti-hCD200 antibody combined with anti-mPD-1 antibody


from clipboard


In vivo antitumor activity of anti-human CD200 (hCD200) antibody when used in combination with anti-mouse PD-1 (mPD-1) antibody. Murine colon cancer B-hCD200 MC38 cells (5x105) were subcutaneously implanted into homozygous B-hCD200/hCD200R mice (female, 6-8-week-old, n=6). Mice were grouped when tumor volume reached approximately 100 mm3, at which time they were intraperitoneally injected with DPBS, anti-mPD-1 antibody alone or in combination with anti-hCD200 antibody BMK (provided by the client). (A) Anti-hCD200 antibody combination with anti-mPD-1 antibody inhibited B-hCD200 MC38 tumor growth in B-hCD200/hCD200R mice. (B) Body weight changes during treatment. As shown in panel A, anti-hCD200 antibody combination with anti-mPD-1 antibody was efficacious in controlling tumor growth in B-hCD200/hCD200R mice, demonstrating that the B-hCD200/hCD200R mice provide a powerful preclinical model for in vivo evaluation of anti-human CD200 antibodies. Values are expressed as mean ± SEM. Significance was determined by two-way ANOVA test. ns P>0.05;*P<=0.05; **P<=0.01.

Note: This experiment was performed by the client using B-hCD200/hCD200R mice. All the other materials were provided by the client.


Functional Analysis


from clipboard

Strain specific TNF-α and IL-10 expression analysis in wild-type C57BL/6 mice and homozygous humanized B-hCD200/hCD200R mice by ELISA. Cell supernatants was collected from spleen and bone marrow of wild-type C57BL/6 mice (+/+) (male, n=3, 7-week-old) and homozygous B-hCD200/hCD200R mice (male, n=3, 7-week-old) stimulated with 5 mg/mL LPS for 24hrs. Expression level of mouse TNF-a and IL-10 were analyzed by ELISA (anti-mouse TNF-α ELISA kit, Biolegend, 430904; anti-mouse IL-10 ELISA kit: Biolegend, 431414). The level of mouse TNF-α and IL-10 were significantly increased in the LPS stimulation group, whereas it was reduced in the LPS and mCD200 protein (Acro, OX2-M82F3) co-stimulation group in wild-type mice. The level of mouse TNF-α and IL-10 were significantly increased in the LPS stimulation group, whereas it was reduced in the LPS and hCD200 protein (Acro, OX2-H5251) co-stimulation group in B-hCD200/hCD200R mice. Significance was determined by two-tailed paired t-test. (*P < 0.05, **P < 0.01, ***P < 0.001)